نتایج جستجو برای: glucagon like peptide 1 hormone
تعداد نتایج: 3413324 فیلتر نتایج به سال:
BACKGROUND In 1906, extracts of mucosa from the porcine upper small intestine were used by Moore et al. as a treatment for diabetes, hoping that “the pancreas secretion might be stimulated by the substance of the nature of a hormone yielded by the duodenal mucosa membrane” (1). In 1932, La Barre named the unidentified substance thought to exert this effect “incretin” (2). Thirty years later, Mc...
Glucagon-like peptide-1 (GLP-1) promotes insulin secretion, inhibits glucagon and repairs pancreatic islet cell function to enhance proliferation regeneration. Furthermore, it includes a mechanism for weight loss angiocarpy protection. This study covers the comparison of GLP-1 agonists with DPP-4 inhibitors GLT-2 inhibitors, agonists, its research possibilities based on summary current clinical...
Silibinin is a natural flavonoid with anti-diabetic activity. Glucagon-like peptide−1 (GLP−1), an intestinal hormone mainly secreted from L cells, which regulates insulin production and sensitivity, appears to be potential therapeutic strategy for T2DM. The current study aims determine the protective effect of silibinin against palmitic acid (PA)-induced damage in GLUTag cells. results revealed...
The global obesity epidemic has resulted in significant morbidity and mortality. However, the medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but carries significant perioperative risks. The gut hormones, peptide tyrosine tyrosine (PYY) and glucagon-like peptide 1 (GLP-1), are elevated following gastric bypass and have been shown to reduce food intake....
OBJECTIVES Reports have suggested a link between treatment with glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancreatitis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon receptors, is currently being investigated as a potential antiobesity therapy, but little is known about its pancreatic safety. The aim of the study was to investigate the acute effect of oxyntomod...
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels. It also improves beta-cell proliferation and prevents beta-cell apoptosis induced by cytotoxic agents. Additionally, glucagon-like peptide-1 delays gastric emptying ...
The proglucagon-derived peptide family consists of three highly related peptides, glucagon and the glucagon-like peptides GLP-1 and GLP-2. Although the biological activity of glucagon as a counter-regulatory hormone has been known for almost a century, studies conducted over the past decade have now also elucidated important roles for GLP-1 as an antidiabetic hormone, and for GLP-2 as a stimula...
In the current context of limited economic and health resources, efficiency of drug treatments is of paramount importance, and their clinical effects and related direct costs should therefore be analyzed. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM) which, in addition to its normoglycemic effects, induces a signi...
DPP4 inhibitors and GLP-1 receptor agonists used in incretin-based strategies treat Type 2 diabetes with different modes of action. The pharmacological blood GLP-1R agonist concentration targets pancreatic and some extrapancreatic GLP-1R, whereas DPP4i favors the physiological activation of the gut-brain-periphery axis that could allow clinicians to adapt the management of Type 2 diabetes, acco...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید